HomeInsightsPE

Zydus Lifesciences Ltd PE Ratio

Zydus Lifesciences Ltd PE Ratio

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

0.0 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 22, 2024

Image

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE

PE

22.2

Last updated on: Nov 22, 2024

Key Highlights

  • The P/E Ratio of Zydus Lifesciences Ltd is 22.2 as of 22 Nov 09:11 AM .
  • The P/E Ratio of Zydus Lifesciences Ltd changed from 19.2 on March 2019 to 26.2 on March 2024 . This represents a CAGR of 5.32% over 6 years.
  • The Latest Trading Price of Zydus Lifesciences Ltd is ₹ 945.5 as of 22 Nov 09:05 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Zydus Lifesciences Ltd

No data available

Company Fundamentals for Zydus Lifesciences Ltd

No data available

Image

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE

Share Price

₹ 945.5

1.25 (0.13%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Zydus Lifesciences Ltd

1M

1Y

3Y

5Y

Monitoring Zydus Lifesciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Nov 2024944.25
19 Nov 2024946.9
18 Nov 2024944.95
14 Nov 2024958.05
13 Nov 2024963.6
12 Nov 2024950.1
11 Nov 2024968.55
08 Nov 2024968.65
07 Nov 2024972.6
06 Nov 2024995

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Zydus Lifesciences Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Zydus Lifesciences Ltd2295,013
Sun Pharmaceuticals Industries Ltd384,26,518
Divis Laboratories Ltd861,58,636
Cipla Ltd251,18,365
Torrent Pharmaceuticals Ltd601,05,067
Mankind Pharma Ltd481,02,273

Key Valuation Metric of Zydus Lifesciences Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical Revenue of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical EBITDA of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical Net Profit of Zydus Lifesciences Ltd

No data available

* All values are in crore

Historical Dividend Payout of Zydus Lifesciences Ltd

No data available

* All values are in %

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products. The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Zydus Lifesciences Ltd News Hub

News

Zydus Life gains as Q1 PAT climbs 31% YoY to Rs 1,420 cr

Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quaret...

Read more

2024-08-09 00:00:00

News

Zydus Lifesciences consolidated net profit rises 30.64% in the June 2024 quarter

Net profit of Zydus Lifesciences rose 30.64% to Rs 1419.90 crore in the quarter ended June...

Read more

2024-08-09 00:00:00

News

Zydus receives USFDA approval for Valbenazine Capsules

Zydus Lifesciences has received final approval from the United States Food and Drug Admini...

Read more

2024-08-09 00:00:00

News

Zydus Lifesciences Ltd soars 1.83%, rises for third straight session

Zydus Lifesciences Ltd is up for a third straight session in a row. The stock is quoting a...

Read more

2024-08-08 00:00:00

News

Stock Alert: Zydus Lifesciences, Dr Reddy's Lab, Shyam Metalics and Energy, KEC International

Securities in F&O ban :Balrampur Chini Mills, Aarti Industries, Aditya Birla Fashion and R...

Read more

2024-08-26 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Zydus Lifesciences Ltd

What is the current PE Ratio of Zydus Lifesciences Ltd?

The Current PE Ratio of Zydus Lifesciences Ltd is 22.21 as on 22 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 22 Nov 2024.

What was the PE Ratio of Zydus Lifesciences Ltd last year?

The PE Ratio of Zydus Lifesciences Ltd was 25.37 last year, now the PE ratio is 22.21, showing a year-on-year growth of -12.5%.

What does the PE Ratio of Zydus Lifesciences Ltd indicate about its stock?

The PE Ratio of Zydus Lifesciences Ltd is 22.21. This ratio indicates that investors are willing to pay 22.21 times the earnings per share for each share of Zydus Lifesciences Ltd.

What is the PE Ratio Growth of Zydus Lifesciences Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Zydus Lifesciences Ltd grew by -12.5% whereas, the EPS ratio grew by -35.8.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*